New Funding Nectar For Hummingbird As It Progresses Novel Antibodies

Hummingbird Bioscience’s business model is based on the development of novel precision therapies against therapeutically significant, but hard-to-drug, targets. It’s an approach in which investors see enough potential to have provided $125m in a Series C financing led by Novo Holdings, the investment and asset management arm linked to Novo Nordisk A/S.

The syndicate of new investors included Amgen Ventures, Morningside Ventures and a fund linked to Singapore’s Economic Development Board, while returnees included the Korean conglomerate SK Inc